Covid vaccine from Germany’s CureVac just 48pc effective, final results show

Covid vaccine from Germany’s CureVac just 48pc effective, final results show
Covid vaccine from Germany’s CureVac just 48pc effective, final results show

Hello and welcome to the details of Covid vaccine from Germany’s CureVac just 48pc effective, final results show and now with the details

Nevin Al Sukari - Sana'a - A woman walks past a board in a testing center for the CureVac vaccine during a study by the German biotech firm CureVac as part of a testing for a new vaccine against Covid-19, in Brussels, Belgium March 2, 2021. — Reuters pic

FRANKFURT, July 1 — Germany’s CureVac announced Wednesday that final trial results showed its coronavirus vaccine had an efficacy rate of just 48 per cent, far lower than those developed by mRNA rivals BioNTech and Moderna.

The outcome had been expected after poor interim results were released earlier this month.

The company in part blamed “the unprecedented context of 15 strains circulating” among the trial volunteers, as well as varying responses across different age groups.

The Covid vaccines developed by German rival BioNTech/Pfizer and US firm Moderna were both approved some 18 months ago after showing around 95 per cent efficacy.

Their trials at the time only had to contend with the original strain of the virus.

CureVac said its jab, known as CVnCoV, did slightly better among people aged 18 to 60 than among older ages, with efficacy climbing to 53 per cent. 

Among that same 18-60 age group, the vaccine offered 100 per cent protection against hospitalisation and death.

“In this final analysis, CVnCoV demonstrates a strong public health value” for people aged 18 to 60, “which we believe will be an important contribution to help manage the Covid-19 pandemic and the dynamic variant spread,” chief executive officer Franz-Werner Haas said in a statement.

CureVac’s late-stage Phase 2b/3 trial involved some 40,000 people in 10 countries in Europe and Latin America. Of those, 228 contracted the coronavirus.

CureVac, founded in 2000 by mRNA pioneer Ingmar Hoerr, said in May that independent analysis “found no safety concerns” with its two-dose vaccine. 

The company said it had shared its data with the European Medicines Agency (EMA) and would give further details at a press conference on Thursday.

Despite being a laggard in the vaccine race, CureVac believes it has advantages over its mRNA competitors.

CureVac’s product can be stored at standard refrigerator temperature, unlike the first-generation Pfizer and Moderna vaccines which require super-cold freezers.

CureVac’s vaccine also requires a lower dosage, allowing for faster and cheaper mass production.

The European Union has secured up to 405 million doses of the CureVac vaccine.

The company is already working on a second-generation vaccine for which it has teamed up with pharma giant GSK. — AFP

These were the details of the news Covid vaccine from Germany’s CureVac just 48pc effective, final results show for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV S.Korea experts call for more Covid curbs as easygoing young fuel surge
NEXT Sydney posts record daily Covid-19 cases, police powers extended to enforce lockdown